SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced publication by the New England Journal of Medicine ...
Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that ...
Tandem Diabetes Care announced plans to link its automated insulin delivery systems with an upcoming wearable monitor from Abbott that aims to measure glucose as well as ketone levels. The dual sensor ...
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today announced that it has entered into a definitive agreement to ...
15 analysts have shared their evaluations of Tandem Diabetes Care (NASDAQ:TNDM) during the recent three months, expressing a mix of bullish and bearish perspectives. In the table below, you'll find a ...
“The strength of our first quarter performance was driven by more than 20% worldwide sales growth, including our highest quarter ever outside the United States,” said John Sheridan, president and ...
Tandem Diabetes Care's top-line growth hasn't been great over the past few years. If it can successfully address challenges detrimental to revenue growth, it may become an attractive stock -- even ...
If you are wondering whether Tandem Diabetes Care at around US$19.89 is starting to look like value or still carries too much risk, you are not alone. The stock has seen a 0.1% decline over the last 7 ...
GAAP margins including GAAP gross margin and GAAP operating margin are calculated using GAAP sales. Non-GAAP margins including non-GAAP gross margin, non-GAAP operating margin, and adjusted EBITDA ...
Hosted on MSN
Improved growth outlook and better-than-expected results boosted Tandem Diabetes Care (TNDM) in Q4
Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” fourth-quarter 2025 investor letter. A copy of the same can be downloaded here. U.S. equity markets experienced a ...
Analysts' ratings for Tandem Diabetes Care (NASDAQ:TNDM) over the last quarter vary from bullish to bearish, as provided by 7 analysts. The table below provides a snapshot of their recent ratings, ...
Tandem Diabetes delivered weaker-than-expected Q4 results but followed with strong forward guidance. The company launched four new products in the U.S. last quarter. Tandem Diabetes climbed as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results